Details of the Drug

General Information of Drug (ID: DMD2GKF)

Drug Name
SFLT-01
Synonyms
AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme
Indication
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 1 [1]
Cross-matching ID
TTD ID
D0YZ4T

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Placenta growth factor (PlGF) TT48I1Y PLGF_HUMAN Modulator [2]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Macular degeneration
ICD Disease Classification 9B78.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01024998) Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). U.S. National Institutes of Health.
2 sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.